These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2159105)

  • 1. [Pharmacology of molsidomine and its active metabolites].
    Böhme E
    Med Klin (Munich); 1990 Feb; 85 Suppl 1():7-10. PubMed ID: 2159105
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty.
    Groves PH; Banning AP; Penny WJ; Newby AC; Cheadle HA; Lewis MJ
    Cardiovasc Res; 1995 Jul; 30(1):87-96. PubMed ID: 7553728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Organic nitrates. New knowledge about the mechanism of action of an old class of substances].
    Schröder H
    Med Monatsschr Pharm; 1992 May; 15(5):134-9. PubMed ID: 1318993
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical use of molsidomine in the treatment of patients with coronary artery diseases].
    Dukát A
    Bratisl Lek Listy; 1996 Aug; 97(8):490-2. PubMed ID: 8963702
    [No Abstract]   [Full Text] [Related]  

  • 5. Histamine up-regulates the generation of nitric oxide, and nitric oxide down-regulates the release of histamine in cardiovascular preparations.
    Mannaioni PF; Bello MG; Di Bello MG; Schunack W; Masini E
    Inflamm Res; 1997 Mar; 46 Suppl 1():S97-8. PubMed ID: 9098784
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of intravenous administration of nitroglycerin and SIN-1 or molsidomine on epicardial arterial diameter in patients with stable coronary heart disease].
    Münzel T; Kurz S; Heitzer T; Luhmann C; Just H
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():38-41. PubMed ID: 7968900
    [No Abstract]   [Full Text] [Related]  

  • 7. The endothelium in acute coronary syndromes.
    Noll G; Lüscher TF
    Eur Heart J; 1998 Apr; 19 Suppl C():C30-8. PubMed ID: 9597423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration].
    Hug J; Hasenfuss G; Wollschläger H; Just HJ; Bonzel T
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():34-7. PubMed ID: 7968899
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the influence of nitrates, molsidomine and SIN-1, a molsidomine metabolite in acute coronary insufficiency.
    Degré S; Sobolski J; Berkenboom G; Abramowicz M; Vandermoten P; Stoupel E
    Bibl Cardiol; 1985; (39):129-34. PubMed ID: 3842256
    [No Abstract]   [Full Text] [Related]  

  • 10. Meeting highlights: nitric oxide donors.
    Ferguson JJ
    Circulation; 1994 Jul; 90(1):4. PubMed ID: 8026024
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of molsidomine preparations on the coronary and myocardial reserves of patients with IHD complicated by circulatory failure].
    Ol'binskaia LI; Sizova ZhM; Alekperov EE
    Ter Arkh; 1994; 66(8):30-2. PubMed ID: 7985149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of thrombocyte function in coronary heart disease. Results with molsidomine (Corvaton)].
    Z Kardiol; 1991; 80 Suppl 5():1-70. PubMed ID: 1776328
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molsidomine in the treatment of ischemic heart disease].
    Sterkowicz S
    Wiad Lek; 1987 Oct; 40(20):1389-95. PubMed ID: 3328427
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of adrenomedullin and calcitonin gene-related peptide on contractions of the rat aorta and porcine coronary artery.
    Yoshimoto R; Mitsui-Saito M; Ozaki H; Karaki H
    Br J Pharmacol; 1998 Apr; 123(8):1645-54. PubMed ID: 9605572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of myocardial ischemia with molsidomine].
    Dirschinger J; Beyerle A; Rudolph W
    Med Klin (Munich); 1990 Mar; 85(3):141-4. PubMed ID: 2186260
    [No Abstract]   [Full Text] [Related]  

  • 16. [Molsidomine in rest and exercise conditions in coronary heart disease. Acute and long-term effects].
    Jansen W; Meyer L; Osterspey A; Eggeling T; Tauchert M; Hilger HH
    Med Klin (Munich); 1986 Jun; 81(14):489-95. PubMed ID: 3097469
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mechanism of the vasodilating effect and blood platelet- antiaggregating activity of molsidomine and SIN-1].
    Kukovetz WR; Holzmann S
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):260-5. PubMed ID: 3031569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the clinical usefulness of molsidomine in ischemic heart disease].
    Janicki K; Ochmański W; Kmieć M
    Pol Tyg Lek; 1986 Jun 23-30; 41(25-26):829-34. PubMed ID: 3534821
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological principles in the development of tolerance.
    Lemmer B
    Z Kardiol; 1985; 74 Suppl 1():33-7. PubMed ID: 2986370
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacology of coronary circulation (author's transl)].
    Takenaka F
    Masui; 1977 Nov; 26(12):1455-60. PubMed ID: 599633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.